At what age should we be vaccinating for human papillomavirus?

Gynecologic and Obstetric Investigation

Volumn 70, Issue 4, 2010, Pages 233-236

  Paavonen, Jorma ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cervical intraepithelial neoplasia; Oncogenic human papillomavirus

Indexed keywords

WART VIRUS VACCINE;

AGE DETERMINATION; CANCER GRADING; CANCER IMMUNIZATION; CANCER SCREENING; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADOLESCENT; ADULT; AGE FACTORS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONDYLOMATA ACUMINATA; FEMALE; FINLAND; HEALTH PLAN IMPLEMENTATION; HUMAN PAPILLOMAVIRUS 11; HUMANS; MALE; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 78649709540     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314011     Document Type: Short Survey

References (19)

1. Barr E, Sings HL: Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008;26:6244-6257.
2. Lehtinen M, French KM, Dillner J, Paavonen J, Garnett G: Sound implementation of human papillomavirus vaccination as a community randomized trial. Therapy 2008;5:289-294.
3. The FUTURE II Study Group: Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine n women with virological evidence of HPV infection. JID 2007;196:1438-1446.
4. The FUTURE II Study Group: Effect of prophylactic human papillomavirus L1 viruslike particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-1868.
5. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler C, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson G A M, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV PATRICIA Study Group: Efficacy of a prophylactic adjuvant bivalent L1 virus-likeparticle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-2170.
6. Paavonen J, Naud P, Salmerón J, et al: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-314.
7. Harper DM, Paavonen J: Age for HPV vaccination. Vaccine 2008;26 S: A7-A11.
8. Hildesheim A, Herrero R: Human papillomavirus vaccine should be given before sexual debut for maximum benefit. JID 2007;196:1431-1432.
9. Jenkins D: A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvant cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008;110: S18-S25.
10. Wheeler CM, Kjaer SK, Sigurdsson K, et al: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 viruslike particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. JID 2009;199:936-944.
11. Brown DR, Kjaer SK, Sigurdsson K, et al: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 viruslike particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. JID 2009;199:926-935.
12. Herrero R: Human papillomavirus (HPV) vaccines: limited cross-protection against additional types. JID 2009;199:919-922.
13. Kahn JA, Burk RD: Papillomavirus vaccines in perspective. Lancet 2007;369:2135-2137.
14. Haugh CJ: Human papillomavirus vaccination: reasons for caution. NEJM 2008;359:861-862.
15. Hildesheim A, Herrero R, Wacholder S, et al: Effect of human papillomavirus 16718 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-753.
16. Garland SM, Hernandez-Avila M, Wheeler CM, et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. NEJM 2007;356:1928-1943. (Pubitemid 46740303)
17. Joura EA, Leodolter S, Hernandez-Avila M, et al: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 2007;369:1693-1702.
18. Woodhall SC, Lehtinen M, Verho T, Huhtala H, Hokkanen M, Kosunen E: Anticipated acceptance of HPV vaccination at the baseline of implementation: A survey of parental and adolescent knowledge and attitudes in Finland. J Adolesc Health 2007;40:466-469.
19. Castle PE, Scarinci I: Should HPV vaccine be given to men? BMJ 2009;339:872-873.